🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

15 recruiting trials

for Multiple Myeloma and Other Plasma Cell Neoplasms

Halt Aging in Survivors of Blood Cancers NCT07292272NA1 site📍 Omaha University of Nebraska · Tests: Behavioral Coaching Intervention, Virtual Exercise Platform Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies NCT06904066Phase 11 site📍 Bethesda National Cancer Institute (NCI) · Tests: aldesleukin, cyclophosphamide, fludarabine phosphate, Individual Patient TCR-Transduced PBL, TruSight Oncology (TSO) 500 A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) NCT01351545n/a142 sites📍 Birmingham📍 Gilbert📍 Phoenix Center for International Blood and Marrow Transplant Resear… · Tests: A multicenter access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs) A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments NCT05137054Phase 142 sites📍 La Jolla📍 Atlanta📍 Indianapolis Regeneron Pharmaceuticals · Tests: Linvoseltamab, Daratumumab, Carfilzomib, Lenalidomide, Bortezomib Non-chemotherapeutic Interventions for the Improvement of Quality of Life and Immune Function in Patients With Multiple Myeloma NCT05312255NA1 site📍 Buffalo Roswell Park Cancer Institute · Tests: Behavioral Intervention, Beta-Adrenergic Antagonist, Propranolol, Quality-of-Life Assessment, Questionnaire Administrat… Longitudinal Data Registry of Plasma Cell Dyscrasia NCT06760052n/a1 site📍 Shanghai Shanghai Zhongshan Hospital A Study of BL-M24D1 in Patients With Relapsed or Refractory Multiple Myeloma and Other Hematologic Malignancies NCT07255898Phase 11 site📍 Chengdu Sichuan Baili Pharmaceutical Co., Ltd. · Tests: BL-M24D1 A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma NCT05372354Phase 1, Phase 217 sites📍 Birmingham📍 Baltimore📍 Boston Bristol-Myers Squibb · Tests: CC-92480, Tazemetostat, BMS-986158, Trametinib, Dexamethasone MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide) NCT06152575Phase 3270 sites📍 Mobile📍 Goodyear📍 Beverly Hills Pfizer · Tests: Elranatamab, Elotuzumab, Pomalidomide, Dexamethasone, Bortezomib A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments NCT05020236Phase 3237 sites📍 Clovis📍 Clovis📍 Fresno Pfizer · Tests: Elranatamab, Daratumumab, Pomalidomide, Dexamethasone A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1) NCT04988555Phase 1, Phase 2104 sites📍 Newport Beach📍 Palo Alto📍 Denver Sumitomo Pharma America, Inc. · Tests: Enzomenib, azoles, Venetoclax, Gilteritinib, Azacitidine (AZA) A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments NCT05714839Phase 1, Phase 244 sites📍 Bullhead City📍 Los Angeles📍 Pembroke Pines GlaxoSmithKline · Tests: Belantamab, Belantamab mafodotin, Pomalidomide, Dexamethasone GPRC5D Targeted PET/CT Imaging in Plasma Cell Disorders NCT07660939Phase 11 site📍 Beijing Peking University First Hospital · Tests: GPRC5D-Targeted PET/CT Imaging Study to Assess Safety and Efficacy of HDP-101 in Chinese Patients With Relapsed or Refractory Multiple Myeloma NCT07529782Phase 15 sites📍 Beijing📍 Suzhou📍 Jinan Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. · Tests: HDP-101 Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors NCT07410494Phase 1, Phase 21 site📍 Beijing Essen Biotech · Tests: EB-SELECT Single-Target CAR-NK Cells, Dual-Target Antigen-Selected CAR-NK
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy